DAVID M MOTT
CIK 1219871 · Vice Chair. of the Board, CEO · last filed 2026-06-23
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.60B
Companies
38
Total Filings
210
Lifetime Open-Market Net
$324.27M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NVAX | Director | 79,770 | $7.95 | $634.2K | -$6.31M | 11 | 2026-06-23 |
| ARDX | Director | 6,831,841 | $4.00 | $27.33M | $65.06M | 31 | 2026-06-18 |
| Mersana Therapeutics, Inc. (MRSN) Delisted | Director | 0 | $29.08 | $0 | $33.01M | 25 | 2026-01-06 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | 19,500,000 | $0.06 | $1.13M | $5.00M | 6 | 2024-07-01 |
| Epizyme, Inc. (EPZM) Delisted | Director | 331,447 | $1.47 | $487.2K | $30.27M | 37 | 2022-07-05 |
| IMRA | Director | 57,306 | $14.59 | $836.1K | $313.6K | 6 | 2022-06-03 |
| Regulus Therapeutics Inc. (RGLS) Delisted | 10%+ Owner | 205,245 | $8.16 | $1.67M | $1.23M | 2 | 2019-12-26 |
| NET | 10%+ Owner | 4,059,376 | $300.27 | $1.22B | $0 | 1 | 2019-09-18 |
| MIRM | 10%+ Owner | 3,736,243 | $100.65 | $376.05M | $6.75M | 1 | 2019-07-24 |
| ASND | Director | 12,000,000 | $255.41 | $3.06B | $49.02M | 8 | 2019-07-03 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | 10%+ Owner | 7,225,676 | $0.00 | $4.3K | $14.69M | 2 | 2019-06-25 |
| NITE | Director | 0 | $38.98 | $0 | $0 | 2 | 2019-06-07 |
| TRVI | 10%+ Owner | 2,938,562 | $18.51 | $54.39M | $25.00M | 1 | 2019-05-13 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | 10%+ Owner | 2,524,386 | $15.00 | $37.87M | $17.12M | 15 | 2019-04-08 |
| TESARO, Inc. (TSRO) Delisted | Director | 0 | — | — | $73.35M | 10 | 2019-01-22 |
| PhaseBio Pharmaceuticals Inc (PHAS) Delisted | 10%+ Owner | 6,641,634 | $0.07 | $465.6K | $90.00M | 1 | 2018-10-24 |
| ESTC | 10%+ Owner | 4,155,995 | $75.11 | $312.16M | $0 | 1 | 2018-10-10 |
| Surface Oncology, Inc. (SURF) Delisted | 10%+ Owner | 3,179,544 | $1.07 | $3.40M | $2.00M | 1 | 2018-04-23 |
| Oruka Therapeutics, Inc. (ABIO) Delisted | 10%+ Owner | 0 | $28.80 | $0 | -$731.3K | 1 | 2018-02-27 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | 10%+ Owner | 10,882,574 | — | — | $0 | 1 | 2018-02-22 |
| APPN | 10%+ Owner | 8,949 | $34.64 | $310.0K | -$66.07M | 4 | 2018-02-15 |
| SYNLOGIC, INC. (SYBX) Delisted | 10%+ Owner | 281,929 | $0.69 | $194.5K | $0 | 2 | 2018-01-26 |
| Care.com Inc (CRCM) Delisted | 10%+ Owner | 504 | — | — | $0 | 2 | 2017-11-08 |
| RYTM | 10%+ Owner | 4,359,956 | $115.63 | $504.14M | $9.35M | 1 | 2017-10-10 |
| MULESOFT, INC (MULE) Delisted | 10%+ Owner | 2,576,939 | — | — | $0 | 1 | 2017-03-22 |
| Achaogen, Inc. (AKAO) Delisted | 10%+ Owner | 5,215,128 | — | — | $6.75M | 1 | 2016-12-19 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | 10%+ Owner | 1,858,450 | — | — | $4.39M | 1 | 2016-10-31 |
| Roka BioScience, Inc. (ROKA) Delisted | 10%+ Owner | 321,681 | — | — | $4.60M | 3 | 2016-09-30 |
| Avalo Therapeutics, Inc. (CERC.U) Delisted | 10%+ Owner | 594,245 | — | — | $0 | 1 | 2015-10-20 |
| SYNLOGIC, INC. (MIRN) Delisted | 10%+ Owner | 1,499,166 | — | — | $6.00M | 1 | 2015-10-06 |
| BOX | 10%+ Owner | 0 | $33.24 | $0 | $0 | 1 | 2015-01-29 |
| CVENT INC (CVT) Delisted | 10%+ Owner | 0 | $8.52 | $0 | -$46.25M | 6 | 2014-11-28 |
| DERM | 10%+ Owner | 3,502,922 | $6.43 | $22.52M | $1.11M | 1 | 2014-10-08 |
| Loxo Oncology, Inc. (LOXO) Delisted | 10%+ Owner | 1,789,420 | — | — | $3.00M | 1 | 2014-08-06 |
| Clovis Oncology, Inc. (CLVS) Delisted | 10%+ Owner | 575 | $0.08 | $47 | $17.11M | 2 | 2013-06-05 |
| WDAY | 10%+ Owner | 1,171 | $179.64 | $210.4K | $0 | 2 | 2013-04-11 |
| Millennial Media Inc. (MM) Delisted | 10%+ Owner | 8,196,614 | — | — | -$21.48M | 2 | 2012-10-30 |
| MEDI | Vice Chair. of the Board, CEO | 599,355 | $33.99 | $20.37M | $0 | 5 | 2007-06-19 |
Recent Filings · Page 6 of 21
210 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-22 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2021-06-21 | ARDX | Grant (A) | — | $0 | EDGAR |
| 2021-06-15 | Mersana Therapeutics, Inc. (MRSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-15 | Epizyme, Inc. (EPZM) Delisted | Grant (A) | +8,060 | $0 | EDGAR |
| 2021-04-01 | Epizyme, Inc. (EPZM) Delisted | Grant (A) | +2,727 | $23.8K | EDGAR |
| 2021-03-29 | Epizyme, Inc. (EPZM) Delisted | Buy (P) | +62,717 | $500.1K | EDGAR |
| 2021-01-20 | Mersana Therapeutics, Inc. (MRSN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-01-05 | Epizyme, Inc. (EPZM) Delisted | Grant (A) | +2,158 | $23.4K | EDGAR |
| 2020-12-15 | Mersana Therapeutics, Inc. (MRSN) Delisted | Other (J) | +1,582 | $0 | EDGAR |
| 2020-12-10 | ARDX | Buy (P) | +170,000 | $1.00M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.